Mycophenolate mofetil for interstitial lung disease in scleroderma
نویسندگان
چکیده
منابع مشابه
Mycophenolate mofetil for scleroderma-related interstitial lung disease: A real world experience
BACKGROUND AND OBJECTIVE Interstitial lung disease (ILD) remains the number one cause of mortality in scleroderma (SSc). Our goal was to determine the effectiveness of mycophenolate mofetil (MMF) in treating SSc-ILD in a retrospective study. METHODS A retrospective, computer-assisted search was performed to identify patients with SSc-ILD treated with MMF from 1997 through 2014. We used a nove...
متن کاملUse of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.
Up to 80% of patients with scleroderma have lung disease, with interstitial lung disease (ILD) being the most common manifestation. Currently, there is no definitive therapy for this condition. The objective of the study is to investigate the use of mycophenolate mofetil (MMF) to treat scleroderma interstitial ILD. We report a retrospective chart review of 17 patients with scleroderma ILD treat...
متن کاملMycophenolate mofetil for localized scleroderma
Commentary Systemic sclerosis is one of the rheumatic diseases that is associated with the worst prognosis. Systemic sclerosis is divided into localized and systemic forms. Localized scleroderma comprises four subtypes, namely morphea, generalized morphea, linear scleroderma and en coup de saber, and is more commonly encountered in children. Although conversion into systemic sclerosis is very u...
متن کاملCyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis
BACKGROUND Scleroderma is a systemic autoimmune disease characterized mainly by skin manifestations and involvement of various visceral organs, especially the lungs. Lung involvement is the leading cause of mortality in patients with scleroderma. There are data to suggest that cyclophosphamide (CYC) and mycophenolate mofetil (MMF) are effective in the management of scleroderma interstitial lung...
متن کاملMycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-related Interstitial Lung Disease: Scleroderma Lung Study II (SLS-II), a double-blind, parallel group, randomised controlled trial
BACKGROUND 12 months of oral cyclophosphamide has been shown to alter the progression of scleroderma-related interstitial lung disease when compared with placebo. However, toxicity was a concern and without continued treatment the efficacy disappeared by 24 months. We hypothesised that a 2 year course of mycophenolate mofetil would be safer, better tolerated, and produce longer lasting improvem...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Rheumatology
سال: 2006
ISSN: 1462-0324,1462-0332
DOI: 10.1093/rheumatology/kel335